INNOCARE(688428) 中国证券报-中证网·2025-04-08 23:09Core Viewpoint - The company, Innovent Biologics, has announced that its oncology pipeline candidates ICP-248, ICP-723, and ICP-B05 will present their latest research findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the advancements in their clinical trials and potential therapeutic applications [1][2][3][4]. Group 1: Project Details - ICP-248 (Mesutoclax): A novel oral BCL2 inhibitor aimed at treating non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML). The company will present preliminary safety and efficacy data for this drug at ASCO [2]. - ICP-723 (Zurletrectinib): A second-generation pan-TRK inhibitor designed for patients with advanced or metastatic solid tumors carrying NTRK gene fusions. The company has submitted a new drug application for this candidate in China and will present data on its efficacy and safety in pediatric patients at ASCO [3]. - ICP-B05 (CM369): An anti-CCR8 monoclonal antibody developed in collaboration with Connoa Biopharmaceuticals, targeting regulatory T cells in the tumor microenvironment. The company is conducting Phase I clinical trials and will present initial results at ASCO [4].